Understanding a monoclonal antibody’s (mAb) mechanism of action (MOA) is fundamental to the discovery of superior therapeutics because a mAb’s epitope largely dictates its biological function.

The LSA is the only fully integrated, high throughput mAb screening and characterization platform that combines patented continuous flow microfluidics with high throughput surface plasmon resonance (SPR) detection to deliver high throughput kinetics and epitope discovery applications to support state-of-the art mAb discovery programs.